West Pharmaceutical stock gains 2.09 percent on CPHI plans

Published on 10/05/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

West Pharmaceutical stock is backed by Q2 2026 revenue of USD 872.3 million, up 13.8 percent year over year. Management raised full-year adjusted EPS guidance to USD 8.85-9.05.

Reinraum-Fertigung von Vials, West Pharmaceutical, ISIN US9523901012 — West Pharmaceutical (ISIN US9523901012) stellt in sterilen Reinräumen Vials und Elastomer-Verschlüsse für Injektionssysteme her, Illustration mit AI erstellt.

West Pharmaceutical stock was trading at USD 372.62 on the NYSE on October 5, 2026 at 11:51 a.m. ET, up 2.09 percent. The company is using CPHI Worldwide in Milan to showcase its SelfDose injector and West Synchrony S1 prefillable syringe system, according to KXAN on October 5, 2026.

SelfDose takes center stage

West will present its patient-controlled injector alongside the Synchrony S1 platform as the company targets drug developers seeking integrated packaging and delivery systems. The CPHI program also includes a technical presentation on combination drug-device development on October 6 and a panel on large-volume drug delivery on October 7, according to KXAN.

The event gives investors a concrete view of West's delivery-device strategy after the second quarter. West said its HVP delivery-device revenue increased 29 percent organically in Q2 2026, while the non-SmartDose business grew at a double-digit rate.

Q2 growth lifts the outlook

West reported Q2 2026 revenue of USD 872.3 million, up 13.8 percent from the prior-year quarter, and adjusted EPS of USD 2.37, up 29 percent, according to Yahoo Finance in the Q2 2026 earnings transcript.

Management raised full-year 2026 organic revenue growth guidance to 10 percent-11 percent from 7 percent-9 percent and set adjusted EPS guidance at USD 8.85-9.05. The same update projected Q3 revenue of USD 820 million-835 million and adjusted EPS of USD 2.14-2.24, while a cyber incident continued to affect West Vantage during Q2.

Consensus target stays near the price

MarketBeat lists a Moderate Buy consensus based on 14 analysts, with an average price target of USD 382.00, a low target of USD 295.00 and a high target of USD 447.00. The average target lies 2.5 percent above the October 5 trading price, leaving the valuation question closely tied to delivery-device growth and the conversion of biologics demand into recurring component volumes.

West Pharmaceutical stock stays elevated

West Pharmaceutical stock was last at USD 372.62 on the NYSE on October 5, 2026 at 11:51 a.m. ET, up 2.09 percent for the session and below its 52-week high of USD 386.00.